Improved Prognosis in HER2-Low Breast Cancer Patients with Reduced Ki67 Index After Neoadjuvant Chemotherapy: A Multi-Center Retrospective Study.

Breast Cancer (Dove Med Press) · 2024 · PMC11472756 · PMID 39403364

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In Cohort 3, patients with HER2-low/δKi67≤-40 also demonstrated a better prognosis compared to those with HER2-low/δKi67>-40, although this difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.